Literature DB >> 20627189

More pieces to the iron chelation puzzle.

Jill Waalen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20627189      PMCID： PMC2949416          DOI： 10.1016/j.trsl.2010.06.006

Source DB:  PubMed          Journal:  Transl Res        ISSN： 1878-1810            Impact factor:   7.012


× No keyword cloud information.
  11 in total

1.  A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.

Authors:  M A Tanner; R Galanello; C Dessi; G C Smith; M A Westwood; A Agus; M Roughton; R Assomull; S V Nair; J M Walker; D J Pennell
Journal:  Circulation       Date:  2007-03-19       Impact factor: 29.690

2.  Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major.

Authors:  Caterina Borgna-Pignatti; Maria Domenica Cappellini; Piero De Stefano; Giovanni Carlo Del Vecchio; Gian Luca Forni; Maria Rita Gamberini; Roberta Ghilardi; Antonio Piga; Maria Antonietta Romeo; Huaqing Zhao; Avital Cnaan
Journal:  Blood       Date:  2005-12-22       Impact factor: 22.113

3.  Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial.

Authors:  Aurelio Maggio; Angela Vitrano; Marcello Capra; Liana Cuccia; Francesco Gagliardotto; Aldo Filosa; Maria Antonietta Romeo; Carmelo Magnano; Vincenzo Caruso; Crocetta Argento; Calogera Gerardi; Saveria Campisi; Pietro Violi; Roberto Malizia; Paolo Cianciulli; Michele Rizzo; Domenico Giuseppe D'Ascola; Alessandra Quota; Luciano Prossomariti; Carmelo Fidone; Paolo Rigano; Alessia Pepe; Gennaro D'Amico; Alberto Morabito; Christian Gluud
Journal:  Br J Haematol       Date:  2009-02-19       Impact factor: 6.998

4.  Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders.

Authors:  Emanuele Angelucci; Giovanni Barosi; Clara Camaschella; Maria Domenica Cappellini; Mario Cazzola; Renzo Galanello; Monia Marchetti; Antonio Piga; Sante Tura
Journal:  Haematologica       Date:  2008-04-15       Impact factor: 9.941

5.  Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture.

Authors:  G Link; A M Konijn; W Breuer; Z I Cabantchik; C Hershko
Journal:  J Lab Clin Med       Date:  2001-08

6.  Combined therapy with deferiprone and desferrioxamine in thalassemia major.

Authors:  Raffaella Origa; Patrizio Bina; Annalisa Agus; Gabriella Crobu; Elisabetta Defraia; Carlo Dessì; GiovanBattista Leoni; Pier Paolo Muroni; Renzo Galanello
Journal:  Haematologica       Date:  2005-10       Impact factor: 9.941

7.  Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.

Authors:  Caterina Borgna-Pignatti; Simone Rugolotto; Piero De Stefano; Huaqing Zhao; Maria Domenica Cappellini; Giovanni Carlo Del Vecchio; Maria Antonietta Romeo; Gian Luca Forni; Maria Rita Gamberini; Roberta Ghilardi; Antonio Piga; Avital Cnaan
Journal:  Haematologica       Date:  2004-10       Impact factor: 9.941

8.  Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience.

Authors:  Nabil Abdelrazik
Journal:  Hematology       Date:  2007-12       Impact factor: 2.269

9.  A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.

Authors:  George J Kontoghiorghes
Journal:  Hemoglobin       Date:  2009       Impact factor: 0.849

10.  Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective.

Authors:  Renzo Galanello
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.